35th week of 2015 patent applcation highlights part 22 |
Patent application number | Title | Published |
20150239894 | Amino Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 2015-08-27 |
20150239895 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 2015-08-27 |
20150239896 | Deuterated Derivatives of Ruxolitinib - The present invention in one embodiment provides a compound of Formula A: | 2015-08-27 |
20150239897 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2015-08-27 |
20150239898 | METHODS FOR MAKING 3-O-PROTECTED MORPHINONES AND 3-O-PROTECTED MORPHINONE DIENOL CARBOXYLATES - Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R | 2015-08-27 |
20150239899 | PRODUCTION METHOD OF HIGH-PURITY NITROGEN-CONTAINING HETEROCYCLIC COMPOUND - A method for producing a high-purity nitrogen-containing heterocyclic compound includes: a process (a) and a process (b): (a) a process of mixing a mixture containing a compound and as an impurity compound with a solvent and a metal salt, and (b) a process of obtaining a mixture in a solution state in which the content of the compound has decreased compared to that in the mixture in the process (a) by filtering a mixed solution obtained in the process (a), or a process of obtaining a mixture in which the content of the compound has decreased compared to that in the mixture in the process (a) by further evaporating the solvent or crystallizing following the filtering; | 2015-08-27 |
20150239900 | INHIBITORS OF KRAS G12C - Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): | 2015-08-27 |
20150239901 | Method For Producing Aromatic Compound - A method for producing a heterocyclic compound represented by general formula (2) from a heterocyclic compound represented by general formula (1) (in the formulae, X1 represents a halogen atom; each of Y1 and Y2 independently represents an oxygen atom, sulfur atom, or selenium atom; each of R1 and R2 independently represents a substituent; m and n respectively represent the number of substituents R1 and R2, each of m and n representing an integer of 0-4; and when m and n are 2 or higher, R1 and R2 may be the same or different and may bond to each other to form an optionally substituted ring). | 2015-08-27 |
20150239902 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity - The invention provides novel imidazol-piperidinyl derivatives of formula (I) | 2015-08-27 |
20150239903 | COMPOUNDS DERIVED FROM 6, 7-DIHYDRO-3H-OXAZOLO [3,4-A] PYRAZINE-5, 8-DIONE - The present invention relates to novel derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione, a mixture of these derivatives. The present invention also encompasses the pharmaceutical compositions comprising an effective amount of a said compounds, object of the present invention, as well as to the use of the compounds and/or derivatives as a phosphodiesterase enzyme inhibitor, and the use of the compounds and/or derivatives in the treatment of erectile dysfunction, disorders and/or conditions treatable with relaxation of tissues and disorders treatable with phosphodiesterase inhibitors, more particularly PDE-5 inhibitor. A further objective of the present invention is to provide a medication comprising a therapeutically effective amount of said compound and a method of treating using the said novel compounds. | 2015-08-27 |
20150239904 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 2015-08-27 |
20150239905 | IMIDAZOPYRIDINE COMPOUNDS - The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders. | 2015-08-27 |
20150239906 | Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid - The present invention aims to provide a method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid with high purity, and a method for producing its derivative. The present invention provides a method for producing a cis-5-hydroxy-2-piperidinecarboxylic acid derivative, which method comprises a step of converting cis-5-hydroxy-2-piperidinecarboxylic acid into a compound(s) of Formula (1) and/or Formula (2) (wherein R | 2015-08-27 |
20150239907 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX - Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer. | 2015-08-27 |
20150239908 | Alkyl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. | 2015-08-27 |
20150239909 | PROCESS FOR THE PREPARATION OF (1S,4S,5S)-4-BROMO-6-OXABICYCLO[3.2.1]OCTAN-7-ONE - The present invention relates to an improved and industrially advantageous process for the preparation of (1S, 4S, 5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one represented by the following formula (1) | 2015-08-27 |
20150239910 | METHOD FOR PREPARATION OF A LEAD-FREE PRIMARY EXPLOSIVE - Described are methods for preparing copper(I) 5-nitrotetrazolate, which include reacting copper(II) sulfate pentahydrate, sodium nitrite, 5-aminotetrazole, and at least one of nitric acid and urea in water. | 2015-08-27 |
20150239911 | METHOD FOR PRODUCING COMPLEX COMPOSED OF ORGANIC NITROGEN COMPOUND AND COPPER (I) SALT OF FLUOROOXO ACID - Disclosed is a method for producing a complex composed of an organic nitrogen compound and a copper (I) salt of a fluorooxo acid with high yield while reducing the corrosion of a reaction vessel. The complex can be produced with high yield while reducing the corrosion of a reaction vessel, by reacting a copper (I) salt, a fluorooxo acid salt and an organic nitrogen compound with one another. | 2015-08-27 |
20150239912 | FATTY ACID AMIDE HYDROLASE INHIBITORS - The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same. | 2015-08-27 |
20150239913 | NOVEL ORGANOSILICON COMPOUNDS, MAKING METHODS, AND ADHESION IMPROVER - Mercapto-containing organosilicon compounds of specific structure are low volatile and serve to enhance the adhesion of resins to inorganic substrates. | 2015-08-27 |
20150239914 | NOVEL ORGANOSILICON COMPOUNDS, MAKING METHODS, AND ADHESION IMPROVER - Mercapto-containing organosilicon compounds of specific structure are low volatile and serve to enhance the adhesion of resins to inorganic substrates. | 2015-08-27 |
20150239915 | SYNTHESIS AND APPLICATIONS OF PERIPHERALLY ASYMMETRIC ARYL POSS COMPOUNDS - A method of synthesizing peripherally asymmetric aryl polyhedral oligomeric silsesquioxane (ArPOSS) compounds. The method comprises: | 2015-08-27 |
20150239916 | TRANSITION METAL COMPOUND HAVING HETEROATOM, CATALYSTIC COMPOSITION INCLUDING THE SAME, AND METHOD FOR PREPARING POLYMERS USING THE SAME - The present invention discloses a transition metal compound having a novel structure and including a heteroatom, a catalyst composition including the same, and a method for preparing polymers using the same. The transition metal compound according to an embodiment of the present invention has good copolymerization properties, and a polymer having a low density may be prepared using thereof. Thus, a copolymer having various uses may be prepared. | 2015-08-27 |
20150239917 | Process of Producing Phosphinothricin Employing Nitrilases - The present invention generally relates to processes for the enzymatic production of a phosphinothricin product or precursor thereof from a nitrile-containing substrate. | 2015-08-27 |
20150239918 | FUNCTIONALIZED CARBON MATRIX MATERIALS - Various embodiments of the present invention provide a functionalized carbon matrix, compositions and composites including the same, and methods of making and using the same. In various embodiments, the present invention provides a functionalized carbon matrix having the structure CM-(NZ-L-FG) | 2015-08-27 |
20150239919 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 2015-08-27 |
20150239920 | Ether Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 2015-08-27 |
20150239921 | Phosphonate Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 2015-08-27 |
20150239922 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION - The present invention provides certain water-soluble O-carbonyl phosphoramidate prodrugs of the following formula I: | 2015-08-27 |
20150239923 | SYNTHESIS OF A TETRASACCHARIDE CONTAINING N-ACETYLLACTOSAMINE - The present invention relates to the synthesis of the tetrasaccharide of formula (I) and novel intermediates used in the synthesis. | 2015-08-27 |
20150239924 | NOVEL CO-MODIFIED ORGANOPOLYSILOXANE, AND POWDER TREATMENT AGENT AND POWDER COMPOSITION COMPRISING THE SAME - A co-modified organopolysiloxane having a group having a siloxane dendron structure and a group containing a saccharide component (e.g. a sugar lactone amide alkyl group) is disclosed. The present invention also provides a method for producing the co-modified organopolysiloxane, as well as a surface treatment agent, a powder treatment agent, a powder composition, a powder-in-oil dispersion, a preparation for external use, and the like containing the co-modified organopolysiloxane. | 2015-08-27 |
20150239925 | Process for Preparing 11-Methylene-18-Methyl-Estr-4-En-3, 17-Dione, Useful as Intermediate Compound for the Synthesis of Molecules Having Pharmacological Activity - There is described a process for the industrial synthesis of 11-methylene-18-methyl-estr-4-en-3,17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of the progestin compounds Desogestrel and Etonogestrel. | 2015-08-27 |
20150239926 | ASYMMETRIC IONIZABLE CATIONIC LIPID FOR RNA DELIVERY - What is described is a compound of formula I | 2015-08-27 |
20150239927 | CRYSTALLINE POLYMORPHIC FORM OF ULIPRISTAL ACETATE - A novel crystalline polymorphic form of ulipristal acetate useful as an agent for preventing and/or treating uterine leiomyoma and as a contraceptive, and a process for producing the crystalline polymorphic form are provided. The novel crystalline polymorphic form of ulipristal acetate is obtained by dissolving an isopropanol-solvated crystal of ulipristal acetate in a mixed solvent containing ethanol and water, and crystallizing an ulipristal acetate from the solution without addition of a seed crystal to the solution. | 2015-08-27 |
20150239928 | CATIONIC STEROIDAL ANTIMICROBIAL COMPOUNDS - Disclosed herein are cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSAs. CSAs may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSAs. | 2015-08-27 |
20150239929 | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR XA DERIVATIVES - Disclosed herein are methods and kits for purifying a serine protease. The methods entail loading the serine protease to a soybean trypsin inhibitor (STI) based affinity chromatograph, and eluting the serine protease with an elution buffer comprising an agent that disrupts interaction between the STI and the serine protease. | 2015-08-27 |
20150239930 | HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. | 2015-08-27 |
20150239931 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES - Novel protein tyrosine phosphatase (PTP) inhibitor compounds synthesized from phosphonodifluoromethyl phenylalanine (F2Pmp) are provided. Use of these compounds for inhibiting a PTP enzyme (such as PTP-MEG2), as well as treating a disease, disorder, or condition associated with inappropriate activity of a PTP (such as type 2 diabetes), is also provided. | 2015-08-27 |
20150239932 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE - The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoetic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage. | 2015-08-27 |
20150239933 | COMPETITIVE INHIBITOR OF GP120 - Peptides and peptide analogs that competitively inhibit HIV protein gp120 and methods for making and using the same. | 2015-08-27 |
20150239934 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer. | 2015-08-27 |
20150239935 | HYDROGEN BOND SURROGATE MACROCYCLES AS MODULATORS OF RAS - The present invention relates to peptides having one or more stable, internally-constrained HBS α-helices, where the peptide is capable of interacting with Ras and related proteins. | 2015-08-27 |
20150239936 | GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY - Described herein are antimicrobial peptides for use in pharmaceutical antibiotic compositions and methods of use thereof. These antimicrobial peptides are Gramicidin A (gA) peptide analogs that, in addition to having potent anti-microbial activity, have greatly increased solubility and significantly reduced toxicity in comparison to the wild-type Gramicidin A peptide. | 2015-08-27 |
20150239937 | PROLINE-LOCKED STAPLED PEPTIDES AND USES THEREOF - The present invention provides a new type of alpha-helix nucleating cross-link (“staple”) formed by olefin metathesis of a proline derivative with an alkenyl side chain and another amino acid derivative with an alkenyl side chain. The proline derivatives as described herein have been found to be strong nucleators of alpha-helix formation. The invention also provides moieties for shielding the free amide N—H's at the N-terminus of an alpha-helix, thereby further stabilizing the helix. The proline derivatives, precursors prior to cross-linking, and the cross-linked peptides are provided as well as methods of using and preparing these compounds and peptides. | 2015-08-27 |
20150239938 | Cell Penetrating Peptides - The present invention relates to a short cell penetrating peptide derived from ZEBRA, optionally linked to a cargo molecule. It also relates to a complex comprising said cell penetrating peptide and a cargo molecule, as well as cells loaded with said complex and the use thereof in therapy and diagnosis. | 2015-08-27 |
20150239939 | Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer - A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18. | 2015-08-27 |
20150239940 | COMPOSITIONS AND METHODS FOR VIRUS INHIBITION - The present invention provides compositions and methods for treating a measles virus infection. A pharmaceutical composition comprises a polypeptide in a biocompatible pharmaceutical carrier, in which the polypeptide consists of at least a portion of SEQ ID NO: 5 or SEQ ID NO: 6. A method embodiment comprises administering the polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a measles infection. | 2015-08-27 |
20150239941 | METHOD FOR EXTRACTING AND STABILISING PHYCOCYANIN AND THE USES THEREOF - Disclosed is a method for extracting and stabilizing phycocyanin from at least one material containing same. The method includes a step of macerating the material or materials in glycerol or a water/glycerol mixture. | 2015-08-27 |
20150239942 | USE OF PEDF-DERIVED POLYPEPTIDES FOR TREATING OSTEOARTHRITIS - A method for treating osteoarthritis in a subject includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. | 2015-08-27 |
20150239943 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION - The present invention relates to polyamide compositions and therapies for treating cells and subjects infected with papilloma virus. | 2015-08-27 |
20150239944 | Product Made of Silk - Disclosed is a method for the production of three-dimensional silk products, wherein a three-dimensional silk product is treated with a silk solvent for a limited period of time so that a partial disintegration of the silk product is obtained whereafter the partially disintegrated silk product is re-stabilised with physical β-sheet induction by a re-stabilising solution. | 2015-08-27 |
20150239945 | COMPOSITIONS AND METHODS FOR INCREASING THE EXPRESSION AND SIGNALLING OF PROTEINS ON CELL SURFACES - The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces. In particular embodiments, the present invention provides nucleic acids and amino acid sequences useful for improving/increasing protein expression on the cell surface. In several embodiments, the sequences are operably linked to the N-terminal end of the protein of interest. The nucleic acid sequence encoding the sequence tag and the protein comprise part of an expression vector. The protein is expressed with the N-terminal sequence tag. In certain embodiments, the sequences of the present invention can be used with one or more chaperone or accessory proteins. In particular embodiments, the one or more chaperone/accessory proteins are encoded by the same vector or separate vectors. In other embodiments, the chaperone/accessory proteins are encoded the same vector that encodes the protein of interest. | 2015-08-27 |
20150239946 | USE OF PEDF-DERIVED POLYPEPTIDES FOR TREATING ALOPECIA AND/OR HAIR DEPIGMENTATION - A method for treating alopecia and/or hair depigmentation includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-44 amino acid residues and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 16-35 of SEQ ID NO: 10. Also disclosed herein are pharmaceutical compositions containing the synthetic peptide; and uses thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in treating alopecia and/or hair depigmentation in a subject. | 2015-08-27 |
20150239947 | CELL-PENETRATING PEPTIDES AND USES THEREOF - The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles. | 2015-08-27 |
20150239948 | ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS - The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases. | 2015-08-27 |
20150239949 | GENETICALLY MODIFIED MICROORGANISMS - Embodiments of the present invention are generally related to genetically modified microorganisms. More specifically, embodiments of the present invention relate to genetically modified microorganisms having the avian follistatin genome engineered therein to create a microorganism strain having the enhanced properties of follistatin. In accordance with one embodiment of the present invention, a method of treating an individual with a muscle degenerative disease comprises administering an effective amount of avian follistatin, wherein the avian follistatin is derived from a genetically modified microorganism. | 2015-08-27 |
20150239950 | DESIGNER LIGANDS OF TGF-BETA SUPERFAMILY - The present disclosure relates to chimeric polypeptide having TGF-beta activity, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides. | 2015-08-27 |
20150239951 | Methods of Treating Neurological Diseases - The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-α. | 2015-08-27 |
20150239952 | COMPOUNDS WITH REDUCED RING SIZE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME - The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 2015-08-27 |
20150239953 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 2015-08-27 |
20150239954 | PROCESS FOR THE PREPARATION OF GELATIN - The present invention relates to a process for preparing gelatin comprising a step of incubating a material comprising collagen with an enzyme composition comprising an acid protease which has at least 70% identity to the amino acid sequence of SEQ ID NO:1, and preparing the gelatin. The invention also relates to gelatin obtained by a process as disclosed herein. | 2015-08-27 |
20150239955 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM ALPHA-1 ANTITRYPSIN AND METHODS OF USE THEREOF - The present invention relates to isolated polypeptides comprising the amino acid sequence of residues 378-413 of | 2015-08-27 |
20150239956 | HIGH-AFFINITY ANTIBODY AND METHOD FOR MANUFACTURING THE SAME - A method for manufacturing a high-affinity antibody including purifying an antibody to which a treatment of reducing the affinity for an antigen is not applied by a temperature responsive protein A medium, in which dissociation constant (K | 2015-08-27 |
20150239957 | Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE - The disclosure provides a fusion polypeptide and compositions useful for treating autoimmune diseases and disorders. The fusion polypeptide comprises a first domain comprising a self antigen which is a conserved sequence found in T cell determinants in the FR1/CDR1 region of VH of human and murine IgG antibodies, particularly SEQ ID NO:2 or an antigenic fragment thereof; and a second domain comprising a heterologous polypeptide or small molecule. | 2015-08-27 |
20150239958 | PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY - The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies. | 2015-08-27 |
20150239959 | Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions - Antibodies and antigen-binding molecules directed against Hepatitis C virus (HCV) are presented. The antibodies and antigen-binding molecules specifically bind to the HCV E1E2 complex. Also provided are pharmaceutical compositions containing the antibodies and/or antigen-binding molecules. Nucleic acids encoding the antibodies and antigen-binding molecules, along with corresponding expression vectors and host cells are also provided. | 2015-08-27 |
20150239960 | MONOCLONAL ANTIBODIES AGAINST INFLUENZA VIRUS GENERATED BY CYCLICAL ADMINISTRATION AND USES THEREOF - Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease. | 2015-08-27 |
20150239961 | ADCC-MEDIATING ANTIBODIES, COMBINATIONS AND USES THEREOF - The present invention relates, in general, to antibody-dependent cellular cytoxicity (ADCC)-mediating antibodies, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of HIV-1 infection in a subject. The invention further relates to compositions comprising such antibodies or antibody fragments. | 2015-08-27 |
20150239962 | Protein A Crystals and Cross-Linked Crystals and Methods of Use Thereof - Protein A crystals and Protein A cross-linked protein crystals (CLPCs) are described. Methods of preparing and using are also disclosed. | 2015-08-27 |
20150239963 | METHODS OF TREATING A TAUOPATHY - The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods. | 2015-08-27 |
20150239964 | Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1 - The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed. | 2015-08-27 |
20150239965 | Treatment - The present invention provides a specific binding molecule which binds to Annexin-1 (Anx-A1) for use in the treatment of T cell-mediated disease. | 2015-08-27 |
20150239966 | COMPLEMENT COMPONENT C5 ANTIBODIES - The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies. | 2015-08-27 |
20150239967 | DRG11-RESPONSIVE (DRAGON) GENE FAMILY - This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and | 2015-08-27 |
20150239968 | MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) - The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth. | 2015-08-27 |
20150239969 | TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY - The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody. | 2015-08-27 |
20150239970 | Stable, Low Viscosity Antibody Formulation - The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-IL6 antibody. In some embodiments, the invention is directed to a stable, low viscosity antibody formulation comprising about 50 mg/mL to about 400 mg/mL of an anti-IL6 antibody, and arginine, wherein the antibody formulation is in an aqueous solution and has a viscosity of less than 20 cP at 23° C. Also provided are methods of making and methods of using such antibody formulations. | 2015-08-27 |
20150239971 | CX3CR1-BINDING POLYPEPTIDES - The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes. | 2015-08-27 |
20150239972 | METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS - PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist. | 2015-08-27 |
20150239973 | Modulation of the Interaction Between SorLA and GDNF-Family Ligand Receptors - The present invention relates to a method to increase the survival of neurons by modulating the interaction between Sor LA and GDNF-family ligand receptors. The agent used to modulate the interaction between the SorLA and GDNF-family ligand receptors are selected from proteins, peptides, antibodies or small organic compounds. The invention also relates to a pharmaceutical compositions comprising these agent as well as the use of said agent or pharmaceutical composition in the treatment of a disease associated with the loss of neurons and/or wherein the survival of neurons are desired. | 2015-08-27 |
20150239974 | HUMANIZED RFB4 ANTI-CD22 ANTIBODY - Disclosed are humanized RFB4 antibodies or antigen-binding fragments thereof. therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, hRFB4 comprises the light and heavy chain RFB4 CDR sequences with human antibody FR and constant region sequences, along with heavy chain framework region (FR) amino acid residues Q1, F27, V48, A49, F68, R98, T117 and light chain residues L4, S22, K39, G100, V104, and K107. More preferably, the heavy and light chain variable region sequences of hRFB4 comprise SEQ ID NO:7 and SEQ ID NO:8, respectively. In certain embodiments, trogocytosis (antigen shaving) induced by hRFB4 plays a significant role in determining antibody efficacy and disease responsiveness for treatment of B-cell diseases, such as hematopoietic cancers, immune system dysfunction and/or autoimmune disease. | 2015-08-27 |
20150239975 | Novel Monoclonal Antibody Which Is Specifically Bound to TM4SF5 Protein and Use Thereof - The present invention relates to a novel monoclonal antibody which is specifically bound to a transmembrane 4 L six family member 5 (TM4SF5) protein. More particularly, the present invention relates to a monoclonal antibody which is specifically bound to a human TM4SF5 protein, to polynucleotides coding for the monoclonal antibody, to an expression vector comprising the nucleotides, to a transformant with the vector introduced thereto, to a method for preparing the monoclonal antibody, to a composition comprising the monoclonal antibody, to a method for treating liver fibrosis using the monoclonal antibody, to a method for treating cancer using the monoclonal antibody, to a method for inhibiting metastasis of cancer, to a method for diagnosing cancer using the monoclonal antibody and to a cancer diagnosis kit comprising the monoclonal antibody. | 2015-08-27 |
20150239976 | Internalizing ErbB2 Antibodies - This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided. | 2015-08-27 |
20150239977 | CD20- AND EGFR-BINDING PROTEINS WITH ENHANCED STABILITY - The invention provides CD20-binding proteins and EGFR-binding proteins having a reduced tendency to aggregate. Compositions and methods of use are also provided. | 2015-08-27 |
20150239978 | ANTIBODIES DIRECTED AGAINST ICOS FOR TREATING GRAFT-VERSUS-HOST DISEASE - The invention relates to a specific antibody directed against, for use for treating graft versus host disease. | 2015-08-27 |
20150239979 | COMPOSITIONS AND METHODS - The invention relates to a composition comprising an anchor region capable of binding to a plasma cell; and a binding region associated with the anchor region, wherein the binding region binds a specific plasma cell antibody. | 2015-08-27 |
20150239980 | ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE - Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin α-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body. | 2015-08-27 |
20150239981 | ANTIBODY FC VARIANTS - The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies. | 2015-08-27 |
20150239982 | NOVEL ANTI-PRESEPSIN ANTIBODY - The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies. | 2015-08-27 |
20150239983 | HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION - The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA. | 2015-08-27 |
20150239984 | THERAPEUTIC FACTOR VIII ANTIBODIES - The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A. | 2015-08-27 |
20150239985 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2015-08-27 |
20150239986 | ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS - Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization | 2015-08-27 |
20150239987 | COMPLEMENT FACTOR Bb ANTIBODIES - The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies. | 2015-08-27 |
20150239988 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 AND METHODS OF USE THEREOF - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 2015-08-27 |
20150239989 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab. | 2015-08-27 |
20150239990 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 2015-08-27 |
20150239991 | PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS - The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G. | 2015-08-27 |
20150239992 | PROCESS FOR PRODUCING CELLULOSE DERIVATIVES OF HIGH BULK DENSITY, GOOD FLOWABILITY AND/OR DISPERSIBILITY IN COLD WATER AS WELL AS LOW SOLUTION COLOR - A particulate cellulose derivative is obtained in a process of grinding and drying a moist cellulose derivative which comprises the steps of A) providing a cellulose derivative having a moisture content of from 60 to 95 percent, based on the total weight of the moist cellulose derivative; B) grinding and partially drying the moist cellulose derivative in a gas-swept impact mill; C) contacting the ground and partially dried cellulose derivative with an additional amount of a drying gas outside the gas-swept impact mill; and D) subjecting the cellulose derivative to partial depolymerization after having contacted the cellulose derivative with a drying gas in step C). The obtained particulate cellulose derivative has a high untapped bulk density, a good flowability and a low color intensity. | 2015-08-27 |
20150239993 | CELLULOSE ETHER CONTAINING CATIONIC GROUP - Provided is a cationic group-containing cellulose ether which, when incorporated in a hair wash, is able to give an excellent smoothness property and its sustained feeling, finger combability and coated feeling in rinsing, and which, when incorporated in a skin cleanser, is able to give an excellent moist feeling to the skin after washing, and also provided are a surfactant composition, a hair wash composition, a skin cleanser composition, a hair conditioner composition and a hair treatment composition containing the cationic group-containing cellulose ether. | 2015-08-27 |